Cargando…
Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial
OBJECTIVE: The aim of this trial was to compare the efficacy of real-time and intermittently scanned continuous glucose monitoring (rtCGM and isCGM, respectively) in maintaining optimal glycemic control. RESEARCH DESIGN AND METHODS: In this randomized study, adults with type 1 diabetes (T1D) and nor...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576432/ https://www.ncbi.nlm.nih.gov/pubmed/32859607 http://dx.doi.org/10.2337/dc20-0112 |
_version_ | 1783598018234155008 |
---|---|
author | Hásková, Aneta Radovnická, Lucie Petruželková, Lenka Parkin, Christopher G. Grunberger, George Horová, Eva Navrátilová, Vendula Kádě, Ondřej Matoulek, Martin Prázný, Martin Šoupal, Jan |
author_facet | Hásková, Aneta Radovnická, Lucie Petruželková, Lenka Parkin, Christopher G. Grunberger, George Horová, Eva Navrátilová, Vendula Kádě, Ondřej Matoulek, Martin Prázný, Martin Šoupal, Jan |
author_sort | Hásková, Aneta |
collection | PubMed |
description | OBJECTIVE: The aim of this trial was to compare the efficacy of real-time and intermittently scanned continuous glucose monitoring (rtCGM and isCGM, respectively) in maintaining optimal glycemic control. RESEARCH DESIGN AND METHODS: In this randomized study, adults with type 1 diabetes (T1D) and normal hypoglycemia awareness (Gold score <4) used rtCGM (Guardian Connect Mobile) or isCGM (FreeStyle Libre) during 4 days of physical activity (exercise phase) and in the subsequent 4 weeks at home (home phase). Primary end points were time in hypoglycemia (<3.9 mmol/L [<70 mg/dL]) and time in range (3.9–10.0 mmol/L [70–180 mg/dL]). The isCGM group wore an additional masked Enlite sensor (iPro2) for 6 days to check for bias between the different sensors used by the rtCGM and isCGM systems. RESULTS: Sixty adults with T1D (mean age 38 ± 13 years; A1C 62 ± 12 mmol/mol [7.8 ± 1.1%]) were randomized to rtCGM (n = 30) or isCGM (n = 30). All participants completed the study. Percentage of time in hypoglycemia (<3.9 mmol/L [<70 mg/dL]) was lower among rtCGM versus isCGM participants in the exercise phase (6.8 ± 5.5% vs. 11.4 ± 8.6%, respectively; P = 0.018) and during the home phase (5.3 ± 2.5% vs. 7.3 ± 4.4%, respectively; P = 0.035). Hypoglycemia differences were significant and most notable during the night. rtCGM participants spent more time in range (3.9–10 mmol/L [70–180 mg/dL]) than isCGM participants throughout both the exercise (78.5 ± 10.2% vs. 69.7 ± 16%, respectively; P = 0.0149) and home (75.6 ± 9.7% vs. 67.4 ± 17.8%, respectively; P = 0.0339) phases. The results were robust to the insignificant bias between rtCGM and isCGM sensors that masked CGM found in the isCGM arm. CONCLUSIONS: rtCGM was superior to isCGM in reducing hypoglycemia and improving time in range in adults with T1D with normal hypoglycemia awareness, demonstrating the value of rtCGM alarms during exercise and in daily diabetes self-management. |
format | Online Article Text |
id | pubmed-7576432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-75764322020-11-02 Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial Hásková, Aneta Radovnická, Lucie Petruželková, Lenka Parkin, Christopher G. Grunberger, George Horová, Eva Navrátilová, Vendula Kádě, Ondřej Matoulek, Martin Prázný, Martin Šoupal, Jan Diabetes Care Emerging Technologies: Data Systems and Devices OBJECTIVE: The aim of this trial was to compare the efficacy of real-time and intermittently scanned continuous glucose monitoring (rtCGM and isCGM, respectively) in maintaining optimal glycemic control. RESEARCH DESIGN AND METHODS: In this randomized study, adults with type 1 diabetes (T1D) and normal hypoglycemia awareness (Gold score <4) used rtCGM (Guardian Connect Mobile) or isCGM (FreeStyle Libre) during 4 days of physical activity (exercise phase) and in the subsequent 4 weeks at home (home phase). Primary end points were time in hypoglycemia (<3.9 mmol/L [<70 mg/dL]) and time in range (3.9–10.0 mmol/L [70–180 mg/dL]). The isCGM group wore an additional masked Enlite sensor (iPro2) for 6 days to check for bias between the different sensors used by the rtCGM and isCGM systems. RESULTS: Sixty adults with T1D (mean age 38 ± 13 years; A1C 62 ± 12 mmol/mol [7.8 ± 1.1%]) were randomized to rtCGM (n = 30) or isCGM (n = 30). All participants completed the study. Percentage of time in hypoglycemia (<3.9 mmol/L [<70 mg/dL]) was lower among rtCGM versus isCGM participants in the exercise phase (6.8 ± 5.5% vs. 11.4 ± 8.6%, respectively; P = 0.018) and during the home phase (5.3 ± 2.5% vs. 7.3 ± 4.4%, respectively; P = 0.035). Hypoglycemia differences were significant and most notable during the night. rtCGM participants spent more time in range (3.9–10 mmol/L [70–180 mg/dL]) than isCGM participants throughout both the exercise (78.5 ± 10.2% vs. 69.7 ± 16%, respectively; P = 0.0149) and home (75.6 ± 9.7% vs. 67.4 ± 17.8%, respectively; P = 0.0339) phases. The results were robust to the insignificant bias between rtCGM and isCGM sensors that masked CGM found in the isCGM arm. CONCLUSIONS: rtCGM was superior to isCGM in reducing hypoglycemia and improving time in range in adults with T1D with normal hypoglycemia awareness, demonstrating the value of rtCGM alarms during exercise and in daily diabetes self-management. American Diabetes Association 2020-11 2020-08-28 /pmc/articles/PMC7576432/ /pubmed/32859607 http://dx.doi.org/10.2337/dc20-0112 Text en © 2020 by the American Diabetes Association https://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license. |
spellingShingle | Emerging Technologies: Data Systems and Devices Hásková, Aneta Radovnická, Lucie Petruželková, Lenka Parkin, Christopher G. Grunberger, George Horová, Eva Navrátilová, Vendula Kádě, Ondřej Matoulek, Martin Prázný, Martin Šoupal, Jan Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial |
title | Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial |
title_full | Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial |
title_fullStr | Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial |
title_full_unstemmed | Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial |
title_short | Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial |
title_sort | real-time cgm is superior to flash glucose monitoring for glucose control in type 1 diabetes: the corrida randomized controlled trial |
topic | Emerging Technologies: Data Systems and Devices |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576432/ https://www.ncbi.nlm.nih.gov/pubmed/32859607 http://dx.doi.org/10.2337/dc20-0112 |
work_keys_str_mv | AT haskovaaneta realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial AT radovnickalucie realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial AT petruzelkovalenka realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial AT parkinchristopherg realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial AT grunbergergeorge realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial AT horovaeva realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial AT navratilovavendula realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial AT kadeondrej realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial AT matoulekmartin realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial AT praznymartin realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial AT soupaljan realtimecgmissuperiortoflashglucosemonitoringforglucosecontrolintype1diabetesthecorridarandomizedcontrolledtrial |